Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of EDP-305 in primary biliary cholangitis
2017-003528-62Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals, Inc.
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EDP-305 in primary biliary cholangitis (PBC) (3 arms), sponsored by Enanta Pharmaceuticals, Inc. Primary endpoint: Primary: ALP response at Week 12. Started May 2018; status: completed.
02
Drugs
EDP-305
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2017-003528-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003528-62.